Early Breast Cancer Highlights From SABCS 2020 Early Breast Cancer Highlights From SABCS 2020
Highlights in early breast cancer from SABCS 2020 include data indicating that more HR+ women can skip adjuvant chemotherapy, and neoadjuvant atezolizumab does not worsen quality of life in early TNBC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2020 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo...
Source: Roche Investor Update - December 23, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo...
Source: Roche Media News - December 23, 2020 Category: Pharmaceuticals Source Type: news

Immediate Breast Reconstruction Feasible Following Neoadjuvant Chemo Immediate Breast Reconstruction Feasible Following Neoadjuvant Chemo
Long-term oncologic outcomes following neoadjuvant chemotherapy for breast cancer are similar with immediate breast reconstruction and conventional mastectomy alone, regardless of response to chemo, according to a retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

' Watch and Wait' Feasible for Some Rectal Cancer Patients
TUESDAY, Nov. 3, 2020 -- A " watch-and-wait " (WW) strategy may be an option for carefully selected patients who achieve a complete response (CR) to neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 3, 2020 Category: Pharmaceuticals Source Type: news

Oncotarget: quantitative ultrasound radiomics in prediction of treatment response for breast cancer
(Impact Journals LLC) The cover for Issue 42 ofOncotarget features Figure 4, " Generation of parametric and texture maps from radiofrequency data, " recently published in " Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer " by Dasgupta, et al. which reported that to investigate quantitative ultrasound based higher-order texture derivatives in predicting the response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 21, 2020 Category: International Medicine & Public Health Source Type: news

Image-Guided Biopsy May Help Some Avoid Breast Cancer Surgery Image-Guided Biopsy May Help Some Avoid Breast Cancer Surgery
Following neoadjuvant chemotherapy, image-guided vacuum-assisted biopsy (VAB) can reliably identify a subgroup of patients with no residual disease in the breast, according to an analysis of pooled data drawn from three continents.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 20, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Dual checkpoint blockade promising as pre-surgical approach for certain patients with localized bladder cancer
(University of Texas M. D. Anderson Cancer Center) Phase I trial finds neoadjuvant combination checkpoint inhibitors (anti-CTLA-4 plus anti-PD-1) was well tolerated and showed early signs of activity in certain patients with bladder cancer. These patients cannot be treated with chemotherapy and have no standard treatment options available. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 12, 2020 Category: Cancer & Oncology Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Investor Update - September 19, 2020 Category: Pharmaceuticals Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Media News - September 19, 2020 Category: Pharmaceuticals Source Type: news

Neoadjuvant Chemoradiotherapy Best Restricted to High-Risk Rectal Cancer Patients Neoadjuvant Chemoradiotherapy Best Restricted to High-Risk Rectal Cancer Patients
Because neoadjuvant chemoradiotherapy in patients with rectal cancer carries a high risk of adverse effects, careful selection is needed to avoid possibly harmful treatment, according to new research.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 3, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Pathological regression of lymph nodes better predicts esophageal cancer survival
(Osaka University) A team of researchers led by Osaka University established a new pathological grading system to evaluate the therapeutic effect of neoadjuvant chemotherapy (NAC) for metastatic lymph nodes (LNs) removed in esophageal cancer (EC) surgery, demonstrating that the system predicts recurrence and prognosis in EC patients better than conventional systems. Their findings will enable 'tailor-made' treatment according to the pathological assessment of all metastatic LNs, eventually improving treatment performance of EC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 27, 2020 Category: International Medicine & Public Health Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Investor Update - June 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Tripl...
Source: Roche Media News - June 18, 2020 Category: Pharmaceuticals Source Type: news

ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® ...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Ascites Cytology Accurately Diagnoses Advanced Ovarian Cancer in Postmenopausal Women Ascites Cytology Accurately Diagnoses Advanced Ovarian Cancer in Postmenopausal Women
Ascites cytology with immunohistochemistry accurately diagnoses advanced ovarian cancer in postmenopausal women and can be used as the basis for neoadjuvant chemotherapy, researchers in Israel report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 29, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

How to Think About Your Cancer Care in the Time of COVID-19
Getting the news that you have cancer is overwhelming and frightening. The COVID-19 crisis adds another layer of anxiety. But know this: you can protect yourself from COVID-19 without compromising your cancer treatment. Don’t panic. In the vast majority of cases, a diagnosis of cancer is not an emergency even though it feels like one. There is time to learn about your options and sort out what is right for you. For now, there will be changes to how we do things. Some of the changes will feel disruptive, but many will lead to better, more patient-centered care. Minimizing your chances of exposure to the virus doesn&rs...
Source: TIME: Health - April 28, 2020 Category: Consumer Health News Authors: Dr. Laura Esserman Tags: Uncategorized COVID-19 Source Type: news

Duke Study Challenges Mesothelioma Chemotherapy Practices
Neoadjuvant chemotherapy — often used before aggressive surgery — has shown no definitive survival benefit for patients with pleural mesothelioma cancer, according to a recent study at the Duke University Medical Center. The study strengthened the growing belief among mesothelioma specialists that the combination of chemotherapy drugs cisplatin and pemetrexed might be a more effective treatment after surgery than before. “I think the study provides a little more evidence to support what those of us were seeing, that (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - April 16, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Advanced Ovarian Cancer: Survival & NAC Use Continue to Increase
Survival of patients with advanced ovarian cancer continues to increase, despite concerns that increased use of neoadjuvant chemotherapy (NAC) could have a negative impact on outcomes. (Source: WebMD Health)
Source: WebMD Health - April 3, 2020 Category: Consumer Health News Source Type: news

Advanced Ovarian Cancer: Survival & NAC Use Continue to Increase Advanced Ovarian Cancer: Survival & NAC Use Continue to Increase
Survival of patients with advanced ovarian cancer continues to increase, despite concerns that increased use of neoadjuvant chemotherapy (NAC) could have a negative impact on outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 2, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Adding Pembrolizumab May Up Response in Triple-Negative Breast Cancer
WEDNESDAY, Feb. 26, 2020 -- For patients with untreated stage II or III triple-negative breast cancer, pembrolizumab plus neoadjuvant chemotherapy, compared with placebo plus neoadjuvant chemotherapy, is associated with a significantly higher rate... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 26, 2020 Category: Pharmaceuticals Source Type: news

SWOG study shows genetic effects of pre-surgical chemo in breast cancer
(SWOG) Results from one of the first studies to determine the effects of pre-surgical, or neoadjuvant, chemotherapy on the breast cancer genome offer up two key insights. One is a before treatment finding that can help predict which patients would most benefit from pre-surgical chemo, and the other an after treatment finding which sheds light on how cancer cells survive chemotherapy. Findings appear in Clinical Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 26, 2020 Category: Cancer & Oncology Source Type: news

FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Investor Update - February 25, 2020 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Media News - February 25, 2020 Category: Pharmaceuticals Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Less chemotherapy may have more benefit in rectal cancer
(University of Colorado Anschutz Medical Campus) GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2020 Category: Cancer & Oncology Source Type: news

Breast Conservation After Neoadjuvant Chemotherapy Less Common in US Than Elsewhere Breast Conservation After Neoadjuvant Chemotherapy Less Common in US Than Elsewhere
Neoadjuvant systemic therapy can facilitate breast conservation in certain women with stage II and III operable breast cancer. But compared to other countries, significantly fewer women in the United States make such a choice.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 15, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer
While adjuvant bisphosphonates are associated with longer survival in postmenopausal women with breast cancer, the same cannot be said for neoadjuvant bisphosphonates.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
             Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, ...
Source: Roche Media News - December 19, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product De...
Source: Roche Investor Update - December 19, 2019 Category: Pharmaceuticals Source Type: news

Omit Surgery in Early-Stage Breast Cancer? Not Yet Omit Surgery in Early-Stage Breast Cancer? Not Yet
It's an enticing idea in an age of breast cancer treatment de-escalation: omit surgery if a patient achieves what looks like a complete response to neoadjuvant chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Julia White, MD, Discusses Tailored Local Therapy Treatment in Breast Cancer
The professor of radiation oncology discussed these tailored treatments for when patients receive neoadjuvant chemotherapy, and they get a complete pathologic response. (Source: CancerNetwork)
Source: CancerNetwork - December 17, 2019 Category: Cancer & Oncology Authors: Julia White, MD Source Type: news

Promising New Neoadjuvant Strategy in Luminal B Breast Cancer Promising New Neoadjuvant Strategy in Luminal B Breast Cancer
The combination of ribociclib and letrozole proved to a viable alternative to standard multidrug neoadjuvant chemotherapy for women with high-risk luminal B breast cancer in an exploratory phase 2 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 16, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Research affirms imaging technique's ability to characterize healthy and non-healthy tissue
(SPIE--International Society for Optics and Photonics) In an article published in the peer-reviewed SPIE publication Journal of Biomedical Optics (JBO), 'Influence of neoadjuvant chemotherapy on diffuse reflectance spectra of tissue in breast surgery specimens,' research observed across 92 ex vivo breast specimens suggests that there is little to no impact on the optical signatures of breast tissue after neoadjuvant chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 27, 2019 Category: Cancer & Oncology Source Type: news

Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast
This case suggests that breast sarcomas could be treated in the same way as other soft tissue sarcomas in terms of adjuvant chemotherapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Laparoscopic Procedures Provide Better Outcomes in Gastric Cancer
Laparoscopy-assisted distal gastrectomy offered better short-term, post-surgical outcomes for patients with locally advanced gastric cancer who were undergoing neoadjuvant chemotherapy.   (Source: CancerNetwork)
Source: CancerNetwork - October 8, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Laparoscopic Gastrectomy May Be Preferable After Gastric-Cancer Chemo Laparoscopic Gastrectomy May Be Preferable After Gastric-Cancer Chemo
In patients with locally advanced gastric cancer, laparoscopy-assisted distal gastrectomy (LADG) after neoadjuvant chemotherapy appears to offer more short-term benefits than does open gastrectomy, according to Chinese researchers.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 8, 2019 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Pembrolizumab Plus Chemo Boosts Response in Triple-Negative Breast Cancer
Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO. (Source: CancerNetwork)
Source: CancerNetwork - September 30, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lymphedema After Axillary Node Dissection Linked With Obesity, Longer Neoadjuvant Chemo Lymphedema After Axillary Node Dissection Linked With Obesity, Longer Neoadjuvant Chemo
Increasing body mass index and longer neoadjuvant chemotherapy (NAC) are associated with a higher risk of lymphedema in women who undergo axillary lymph node dissection, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Skipping Surgery in Rectal Cancer: Better or Worse? Skipping Surgery in Rectal Cancer: Better or Worse?
' Unreliable'assessment of complete clinical response after neoadjuvant chemoradiotherapy for rectal cancer means a watch-and-wait strategy should be followed with caution, suggest results of an expert debate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Pick the Winner' Trial in Rectal Cancer: Chemoradiation First'Pick the Winner' Trial in Rectal Cancer: Chemoradiation First
A'pick the winner'trial found that chemoradiation followed by chemo wins in total neoadjuvant therapy for locally advanced rectal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 5, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Can T-DM1 Match Chemotherapy Plus Dual Blockade in HER2+ Breast Cancer?
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Nintedanib Worsens Outcomes Along With Chemo in Advanced Ovarian Cancer
A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer
In the majority of studied patients with locally advanced pancreatic cancer, total neoadjuvant treatment with fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) along with losartan and chemoradiation allowed complete tumor removal, according to a single-arm phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

NRG trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe
(NRG Oncology) Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction chemotherapy followed by chemoradiotherapy and surgery; TNT) in patients with locally advanced rectal adenocarcinoma on the NRG Oncology Phase II clinical trial NRG-GI002 were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2019 Category: Cancer & Oncology Source Type: news

Packing a PUNCH in Prostate Cancer: Chemo & ADT & Surgery Packing a PUNCH in Prostate Cancer: Chemo & ADT & Surgery
Investigators of the Preoperative Use of Neoadjuvant Chemotherapy (PUNCH) trial say that this experimental approach should now be a standard in high-risk, localized disease. An expert rejects the idea.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 7, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Lesions ID'd on Breast MRI During Treatment Likely Benign
TUESDAY, May 7, 2019 -- For patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer, magnetic resonance imaging (MRI) examinations with new suspicious findings are unlikely to represent a new site of malignancy, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 7, 2019 Category: Pharmaceuticals Source Type: news